A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib

In this study, we delved into the safety profile of alpelisib, an FDA-approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, and PIK3CA-Related Overgrowth Spectrum (PROS). Despite its approval, real-world, long-term safety data is lackin...

Full description

Bibliographic Details

Published in:	Heliyon
Main Authors:	Yu Lin, Xinlei Zheng, Yan Chen, Qichun Nian, Li Lin, Maohua Chen
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Subjects:	Alpelisib Adverse event FAERS database Disproportionality analysis Pharmacovigilance
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844024035606